Latest Breaking News On - Urogen pharma ltd - Page 12 : comparemela.com

UroGen Pharma Ltd (NASDAQ:URGN) Sees Large Growth in Short Interest

UroGen Pharma Ltd. (NASDAQ:URGN – Get Free Report) was the target of a significant increase in short interest in July. As of July 31st, there was short interest totalling 1,570,000 shares, an increase of 55.4% from the July 15th total of 1,010,000 shares. Based on an average trading volume of 553,600 shares, the short-interest ratio […]

Urogen pharmaUrogen pharma company profileUrogen pharma ltdNorthern trust corpBlackrock incMillennium managementGeode capital managementStonepine capital managementGet free reportGen pharmaCapital managementTrust corpGen pharma ltdUrogen pharma dailyNasdaq urgn

UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments

Both ENVISION and ATLAS Phase 3 trials of UGN-102 met primary endpoints in treating low-grade intermediate-risk non‐muscle‐invasive bladder cancer . Reported record JELMYTO® net product. -Today at 08:05 am- MarketScreener

Urogen pharmaUrogen rtgelLiz barrettUrogen pharma ltdDrug administrationChief executive officerNew drug applicationPrepaid forward obligationLong term debtPharmakon advisorsCash equivalentsOperating expenseWebcast informationUpper tract urothelial cancerPrescribing informationPatient information

UroGen Pharma Ltd Q2 Loss decreases, beats estimates

UroGen Pharma Ltd. (URGN) released Loss for second quarter that decreased from last year and beat the Street estimates. The company's earnings totaled -$24.14 million, or -$1.

Thomson reutersUrogen pharma ltdUrogen pharmaGen pharmaAnalyst estimatesWall streetOrporate resultsUsiness newsRogen pharma ltd

UroGen Pharma (URGN) Scheduled to Post Earnings on Thursday

UroGen Pharma (NASDAQ:URGN – Get Free Report) is scheduled to be announcing its earnings results before the market opens on Thursday, August 10th. Analysts expect the company to announce earnings of ($1.13) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link. UroGen […]

United statesUrogen pharmaMillennium managementStonepine capital managementWells fargo companyUrogen pharma ltdAmerica corpGet free reportGen pharmaCapital managementJane street groupGen pharma ltdUrogen pharma dailyNasdaq urgn

Bladder Cancer Market Likely To Exhibit Substantial Growth, Assesses Delveinsight | Leading Companies - Ciclomed, Bristol-Myers Squibb, Cg Oncology, M

Bladder Cancer Market Likely To Exhibit Substantial Growth, Assesses Delveinsight | Leading Companies - Ciclomed, Bristol-Myers Squibb, Cg Oncology, M
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesFidia farmaceuticiBristol myers squibbEli lillyPrnewswire delveinsightAstellas pharma inc incyte corporationJanssen research developmentTaiho oncology incMerck sharp dohmeIncyte corporationUrogen pharma ltdCg oncology incOncology incSeagen incDgene inc